INFANT BACTERIAL THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 89 SEK | +1.14% |
|
+0.23% | -1.11% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâs focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Sector
Pharmaceuticals
Calendar
10:00am
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -1.11% | 110M | |
| +6.97% | 71.94B | |
| -10.86% | 5.13B | |
| +46.43% | 4.66B | |
| +5.38% | 3.97B | |
| -16.20% | 2.55B | |
| +21.10% | 2.41B | |
| -26.20% | 2.36B | |
| +19.92% | 2.21B | |
| +8.10% | 1.71B |
- Stock Market
- Equities
- IBT B Stock
- News Infant Bacterial Therapeutics AB
- Sweden’s Infant Bacterial Therapeutics to Raise SEK101 Million via Rights Issue